The prognosis for certain localized cancers, such as Stage II melanoma and Stage IA/IB non-small cell lung cancer is uncertain. Following curative-intent resection of the primary tumor, the long-term (5- or 10-year) overall survival for these patients can hover around 50%. At the same time, the morbidities associated with available adjuvant therapies precludes their use in the majority of these patients. Current prognostic models derived from conventional clinicopathologic parameters are insufficient to identify, at the time of diagnosis, the subset of patients at highest risk of recurrence for selective adjuvant therapy administration. The goal of my research program is to develop novel prognostic models for both early-stage non-small cell lung cancer and melanoma. Variables reflecting characteristics of the index tumor (somatic mutations, differential transcript profiling, differential protein expression), the patient's germline genetics as well as lifestyle behaviors are all simultaneously considered.
Extensive Research Description
1. Molecular prognostic models for cutaneous melanoma metastases
2. Mechanisms of benign metastasis in kidney angiomyolipomas
3. Radiogenomics in lung cancer
4. Energy balance in Stage I non-small cell lung cancer prognosis
- Gould Rothberg BE, Bracken MB, Rimm DL. 2009. Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and meta-analysis. Journal of the National Cancer Institute 101(7):452-474.
- Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM & Rimm DL. 2009. A melanoma prognostic model using tissue microarrays and genetic algorithms. Journal of Clinical Oncology 27(34): 5772-5780.
- Gould Rothberg BE, Magriples U, Kershaw TS, Rising SS & Ickovics JR. 2011. Gestational weight gain and subsequent post-partum weight loss among young, low-income ethnic minority women. American Journal of Obstetrics and Gynecology 204(1): 52. e1-e11.